 Matthew Greenhawt
Concepts (516)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 100 | 2024 | 253 | 28.720 |
Why?
| | Peanut Hypersensitivity | 66 | 2023 | 197 | 24.610 |
Why?
| | Anaphylaxis | 56 | 2023 | 148 | 20.720 |
Why?
| | Allergens | 74 | 2024 | 413 | 12.270 |
Why?
| | Desensitization, Immunologic | 36 | 2024 | 117 | 10.570 |
Why?
| | Arachis | 47 | 2023 | 146 | 10.500 |
Why?
| | Epinephrine | 29 | 2023 | 164 | 9.240 |
Why?
| | Hypersensitivity | 29 | 2023 | 254 | 8.980 |
Why?
| | Egg Hypersensitivity | 19 | 2023 | 45 | 6.580 |
Why?
| | Cost-Benefit Analysis | 25 | 2023 | 545 | 5.260 |
Why?
| | Drug Hypersensitivity | 11 | 2023 | 85 | 4.880 |
Why?
| | Pandemics | 21 | 2022 | 1319 | 4.100 |
Why?
| | Skin Tests | 26 | 2022 | 122 | 4.030 |
Why?
| | Asthma | 31 | 2023 | 2032 | 3.960 |
Why?
| | Eczema | 17 | 2023 | 81 | 3.820 |
Why?
| | Pneumonia, Viral | 10 | 2020 | 340 | 3.800 |
Why?
| | Coronavirus Infections | 10 | 2020 | 332 | 3.790 |
Why?
| | Allergy and Immunology | 14 | 2020 | 51 | 3.750 |
Why?
| | Eosinophilic Esophagitis | 14 | 2023 | 296 | 3.730 |
Why?
| | Caregivers | 16 | 2023 | 717 | 3.650 |
Why?
| | Humans | 287 | 2024 | 114757 | 3.480 |
Why?
| | Quality of Life | 32 | 2024 | 2358 | 3.100 |
Why?
| | Vaccines | 8 | 2023 | 375 | 3.070 |
Why?
| | Influenza Vaccines | 10 | 2018 | 498 | 2.700 |
Why?
| | Betacoronavirus | 7 | 2020 | 252 | 2.690 |
Why?
| | Child | 95 | 2024 | 18352 | 2.620 |
Why?
| | Practice Guidelines as Topic | 26 | 2024 | 1393 | 2.560 |
Why?
| | Dermatitis, Atopic | 13 | 2023 | 307 | 2.560 |
Why?
| | Nut Hypersensitivity | 5 | 2019 | 9 | 2.450 |
Why?
| | Food | 15 | 2024 | 160 | 2.440 |
Why?
| | Immunoglobulin E | 24 | 2023 | 316 | 2.430 |
Why?
| | Immunotherapy | 14 | 2023 | 475 | 2.380 |
Why?
| | Urticaria | 5 | 2022 | 50 | 2.370 |
Why?
| | Health Care Costs | 5 | 2022 | 380 | 2.230 |
Why?
| | Milk Hypersensitivity | 5 | 2023 | 22 | 2.210 |
Why?
| | Infant | 58 | 2023 | 7935 | 2.180 |
Why?
| | Enterocolitis | 6 | 2020 | 33 | 2.060 |
Why?
| | Hypersensitivity, Immediate | 4 | 2023 | 46 | 2.040 |
Why?
| | Vaccination | 13 | 2022 | 1205 | 1.960 |
Why?
| | Influenza, Human | 7 | 2018 | 546 | 1.940 |
Why?
| | Child, Preschool | 47 | 2023 | 9079 | 1.910 |
Why?
| | School Health Services | 4 | 2020 | 206 | 1.810 |
Why?
| | Infant Nutritional Physiological Phenomena | 7 | 2023 | 133 | 1.660 |
Why?
| | United States | 49 | 2023 | 12176 | 1.650 |
Why?
| | Omalizumab | 4 | 2020 | 45 | 1.560 |
Why?
| | Risk | 10 | 2020 | 815 | 1.490 |
Why?
| | Dietary Exposure | 3 | 2019 | 7 | 1.470 |
Why?
| | Rhinitis, Allergic | 5 | 2023 | 35 | 1.470 |
Why?
| | Injections, Intramuscular | 6 | 2023 | 117 | 1.390 |
Why?
| | Allergists | 7 | 2023 | 19 | 1.340 |
Why?
| | Decision Support Techniques | 4 | 2020 | 351 | 1.320 |
Why?
| | Bronchodilator Agents | 6 | 2023 | 240 | 1.310 |
Why?
| | Milk | 7 | 2023 | 124 | 1.310 |
Why?
| | Sympathomimetics | 2 | 2019 | 25 | 1.290 |
Why?
| | Surveys and Questionnaires | 21 | 2023 | 4625 | 1.280 |
Why?
| | Anti-Asthmatic Agents | 5 | 2021 | 349 | 1.280 |
Why?
| | Immune Tolerance | 7 | 2019 | 328 | 1.220 |
Why?
| | Primary Prevention | 7 | 2022 | 172 | 1.210 |
Why?
| | Cost of Illness | 3 | 2021 | 254 | 1.200 |
Why?
| | Population Groups | 3 | 2019 | 57 | 1.200 |
Why?
| | Patient-Centered Care | 5 | 2021 | 474 | 1.200 |
Why?
| | Health Literacy | 3 | 2020 | 164 | 1.180 |
Why?
| | Health Policy | 4 | 2020 | 334 | 1.150 |
Why?
| | Emergency Medical Services | 7 | 2021 | 587 | 1.140 |
Why?
| | Canada | 10 | 2022 | 322 | 1.100 |
Why?
| | Self Administration | 4 | 2020 | 123 | 1.090 |
Why?
| | Eggs | 5 | 2023 | 30 | 1.080 |
Why?
| | Delivery of Health Care | 5 | 2020 | 833 | 1.080 |
Why?
| | Social Media | 5 | 2020 | 132 | 1.070 |
Why?
| | Female | 67 | 2023 | 59507 | 1.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 242 | 1.070 |
Why?
| | Schools | 6 | 2021 | 399 | 1.010 |
Why?
| | Patient Participation | 4 | 2024 | 360 | 1.010 |
Why?
| | Age Factors | 14 | 2020 | 2890 | 0.990 |
Why?
| | Communication | 3 | 2020 | 747 | 0.980 |
Why?
| | Evidence-Based Medicine | 7 | 2020 | 667 | 0.960 |
Why?
| | Checklist | 2 | 2023 | 83 | 0.940 |
Why?
| | Practice Patterns, Physicians' | 7 | 2023 | 1178 | 0.930 |
Why?
| | Adolescent | 33 | 2023 | 17808 | 0.920 |
Why?
| | Health Personnel | 3 | 2021 | 574 | 0.900 |
Why?
| | Personal Protective Equipment | 2 | 2020 | 50 | 0.880 |
Why?
| | Rhinitis | 3 | 2022 | 128 | 0.870 |
Why?
| | Male | 51 | 2023 | 55579 | 0.860 |
Why?
| | Biological Products | 2 | 2023 | 167 | 0.860 |
Why?
| | Probiotics | 2 | 2023 | 46 | 0.840 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 9 | 2019 | 28 | 0.830 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 101 | 0.830 |
Why?
| | Telemedicine | 5 | 2022 | 663 | 0.810 |
Why?
| | Clinical Decision-Making | 4 | 2020 | 268 | 0.790 |
Why?
| | Gastritis | 1 | 2023 | 84 | 0.790 |
Why?
| | Infant Formula | 2 | 2023 | 74 | 0.780 |
Why?
| | Enteritis | 1 | 2023 | 82 | 0.780 |
Why?
| | Milk Proteins | 3 | 2022 | 36 | 0.780 |
Why?
| | Rhinitis, Allergic, Seasonal | 2 | 2019 | 32 | 0.780 |
Why?
| | Sublingual Immunotherapy | 2 | 2022 | 7 | 0.770 |
Why?
| | Food Labeling | 4 | 2019 | 17 | 0.770 |
Why?
| | Anti-Bacterial Agents | 4 | 2023 | 1477 | 0.740 |
Why?
| | Penicillins | 2 | 2021 | 52 | 0.740 |
Why?
| | Siblings | 2 | 2019 | 222 | 0.730 |
Why?
| | Nuts | 2 | 2019 | 12 | 0.730 |
Why?
| | Eosinophilia | 1 | 2023 | 186 | 0.730 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.720 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2013 | 139 | 0.710 |
Why?
| | Physicians | 4 | 2021 | 772 | 0.700 |
Why?
| | Women's Health | 1 | 2022 | 271 | 0.700 |
Why?
| | Adult | 34 | 2023 | 30548 | 0.700 |
Why?
| | Administration, Oral | 10 | 2024 | 731 | 0.700 |
Why?
| | Dietary Proteins | 3 | 2020 | 123 | 0.680 |
Why?
| | Consensus | 6 | 2023 | 535 | 0.680 |
Why?
| | Markov Chains | 5 | 2022 | 114 | 0.680 |
Why?
| | Diet | 8 | 2022 | 1080 | 0.670 |
Why?
| | Observation | 1 | 2019 | 50 | 0.670 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2018 | 1183 | 0.670 |
Why?
| | Inservice Training | 1 | 2020 | 105 | 0.670 |
Why?
| | Patient Care | 1 | 2020 | 103 | 0.660 |
Why?
| | Anti-Allergic Agents | 1 | 2019 | 41 | 0.660 |
Why?
| | Bites and Stings | 1 | 2019 | 30 | 0.660 |
Why?
| | Risk Reduction Behavior | 3 | 2018 | 201 | 0.660 |
Why?
| | Carmine | 2 | 2009 | 2 | 0.660 |
Why?
| | Infection Control | 1 | 2020 | 135 | 0.660 |
Why?
| | Job Satisfaction | 1 | 2021 | 168 | 0.660 |
Why?
| | Juglans | 1 | 2019 | 7 | 0.660 |
Why?
| | Aircraft | 1 | 2019 | 26 | 0.650 |
Why?
| | Biological Therapy | 1 | 2019 | 27 | 0.650 |
Why?
| | Evidence-Based Practice | 2 | 2020 | 185 | 0.640 |
Why?
| | Burnout, Professional | 2 | 2021 | 322 | 0.630 |
Why?
| | Pathology, Molecular | 1 | 2019 | 26 | 0.630 |
Why?
| | Multiphasic Screening | 1 | 2018 | 2 | 0.620 |
Why?
| | Protein Hydrolysates | 1 | 2018 | 7 | 0.620 |
Why?
| | Health Promotion | 3 | 2023 | 686 | 0.620 |
Why?
| | Immunomodulation | 2 | 2019 | 84 | 0.620 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 172 | 0.620 |
Why?
| | Polysorbates | 3 | 2023 | 35 | 0.610 |
Why?
| | Population | 1 | 2018 | 28 | 0.610 |
Why?
| | Students | 3 | 2017 | 501 | 0.610 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 212 | 0.610 |
Why?
| | Watchful Waiting | 1 | 2018 | 55 | 0.610 |
Why?
| | Research Design | 4 | 2023 | 931 | 0.590 |
Why?
| | Food, Genetically Modified | 1 | 2017 | 3 | 0.590 |
Why?
| | Prejudice | 1 | 2018 | 55 | 0.590 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 35 | 0.590 |
Why?
| | Air Travel | 2 | 2018 | 2 | 0.590 |
Why?
| | Plants, Genetically Modified | 1 | 2017 | 18 | 0.590 |
Why?
| | Environmental Exposure | 2 | 2018 | 374 | 0.590 |
Why?
| | Plant Proteins | 1 | 2018 | 81 | 0.580 |
Why?
| | Crops, Agricultural | 1 | 2017 | 28 | 0.580 |
Why?
| | Home Care Services | 1 | 2020 | 222 | 0.570 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 664 | 0.560 |
Why?
| | Public Health | 2 | 2020 | 434 | 0.540 |
Why?
| | Esophagus | 3 | 2019 | 226 | 0.540 |
Why?
| | Risk Assessment | 8 | 2023 | 2973 | 0.540 |
Why?
| | Student Health Services | 2 | 2014 | 16 | 0.540 |
Why?
| | Eosinophils | 3 | 2020 | 278 | 0.540 |
Why?
| | Advisory Committees | 7 | 2024 | 208 | 0.530 |
Why?
| | Quality of Health Care | 1 | 2020 | 573 | 0.520 |
Why?
| | Influenza A virus | 2 | 2015 | 90 | 0.520 |
Why?
| | Proton Pump Inhibitors | 5 | 2020 | 96 | 0.520 |
Why?
| | Mastocytosis | 2 | 2023 | 12 | 0.520 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 248 | 0.510 |
Why?
| | Breast Feeding | 6 | 2023 | 370 | 0.500 |
Why?
| | Psychometrics | 2 | 2022 | 607 | 0.500 |
Why?
| | Trust | 1 | 2016 | 105 | 0.500 |
Why?
| | Immunization | 4 | 2019 | 401 | 0.490 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 121 | 0.490 |
Why?
| | Angioedema | 1 | 2015 | 16 | 0.490 |
Why?
| | Health Status Indicators | 1 | 2015 | 156 | 0.480 |
Why?
| | Drug Labeling | 1 | 2014 | 42 | 0.470 |
Why?
| | Antigens, Plant | 4 | 2019 | 47 | 0.470 |
Why?
| | Young Adult | 13 | 2020 | 10463 | 0.460 |
Why?
| | United Kingdom | 5 | 2023 | 226 | 0.460 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 450 | 0.460 |
Why?
| | Referral and Consultation | 2 | 2015 | 632 | 0.450 |
Why?
| | Ovalbumin | 2 | 2013 | 161 | 0.450 |
Why?
| | Health Services Accessibility | 1 | 2020 | 763 | 0.450 |
Why?
| | Mass Screening | 2 | 2019 | 1003 | 0.450 |
Why?
| | Adrenal Cortex Hormones | 6 | 2023 | 498 | 0.440 |
Why?
| | Cross-Sectional Studies | 8 | 2023 | 4409 | 0.430 |
Why?
| | Retrospective Studies | 13 | 2022 | 12515 | 0.430 |
Why?
| | Iron-Dextran Complex | 2 | 2023 | 9 | 0.430 |
Why?
| | Comorbidity | 4 | 2021 | 1449 | 0.430 |
Why?
| | Decision Making | 4 | 2020 | 781 | 0.430 |
Why?
| | Polyethylene Glycols | 3 | 2023 | 561 | 0.420 |
Why?
| | Excipients | 2 | 2023 | 49 | 0.420 |
Why?
| | Immunologic Tests | 3 | 2020 | 16 | 0.420 |
Why?
| | Glucocorticoids | 4 | 2020 | 532 | 0.410 |
Why?
| | Animals | 21 | 2023 | 31762 | 0.410 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2015 | 221 | 0.410 |
Why?
| | Middle Aged | 15 | 2022 | 26757 | 0.400 |
Why?
| | Internet | 1 | 2016 | 596 | 0.400 |
Why?
| | Bacterial Proteins | 1 | 2017 | 739 | 0.390 |
Why?
| | Psychology, Educational | 1 | 2011 | 4 | 0.380 |
Why?
| | Feeding Behavior | 1 | 2017 | 574 | 0.380 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2022 | 61 | 0.370 |
Why?
| | Health Status Disparities | 1 | 2013 | 201 | 0.370 |
Why?
| | Mental Health | 3 | 2021 | 560 | 0.370 |
Why?
| | Insect Bites and Stings | 2 | 2023 | 13 | 0.370 |
Why?
| | Medical Overuse | 2 | 2021 | 31 | 0.360 |
Why?
| | Diet Therapy | 3 | 2017 | 36 | 0.360 |
Why?
| | Infant, Newborn | 9 | 2021 | 5035 | 0.360 |
Why?
| | Pregnancy Complications | 1 | 2015 | 429 | 0.360 |
Why?
| | Time Factors | 7 | 2020 | 6124 | 0.350 |
Why?
| | Treatment Outcome | 11 | 2024 | 9089 | 0.350 |
Why?
| | Cattle | 3 | 2023 | 921 | 0.340 |
Why?
| | Disease Management | 5 | 2021 | 560 | 0.340 |
Why?
| | Gastroenterology | 3 | 2020 | 159 | 0.340 |
Why?
| | Sensitivity and Specificity | 3 | 2019 | 1691 | 0.330 |
Why?
| | RNA, Messenger | 3 | 2021 | 2557 | 0.330 |
Why?
| | Pigments, Biological | 1 | 2009 | 13 | 0.330 |
Why?
| | Cohort Studies | 6 | 2022 | 4901 | 0.330 |
Why?
| | Weaning | 2 | 2020 | 48 | 0.320 |
Why?
| | Self Care | 3 | 2017 | 350 | 0.310 |
Why?
| | Azithromycin | 1 | 2009 | 80 | 0.300 |
Why?
| | Physician-Patient Relations | 3 | 2024 | 462 | 0.300 |
Why?
| | Double-Blind Method | 4 | 2023 | 1662 | 0.300 |
Why?
| | Administration, Cutaneous | 3 | 2023 | 117 | 0.300 |
Why?
| | Emergencies | 2 | 2019 | 146 | 0.290 |
Why?
| | Anxiety | 4 | 2021 | 842 | 0.290 |
Why?
| | Pregnancy | 6 | 2023 | 5525 | 0.290 |
Why?
| | Pediatricians | 2 | 2020 | 122 | 0.290 |
Why?
| | Health Status | 3 | 2021 | 723 | 0.280 |
Why?
| | Goals | 2 | 2018 | 149 | 0.280 |
Why?
| | Prospective Studies | 8 | 2022 | 6217 | 0.270 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2539 | 0.270 |
Why?
| | Administration, Sublingual | 2 | 2018 | 13 | 0.270 |
Why?
| | Prevalence | 6 | 2022 | 2249 | 0.270 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 680 | 0.260 |
Why?
| | Chronic Disease | 3 | 2022 | 1590 | 0.260 |
Why?
| | Administration, Topical | 3 | 2020 | 139 | 0.260 |
Why?
| | Egg Proteins | 2 | 2016 | 19 | 0.260 |
Why?
| | Vaccines, Inactivated | 2 | 2018 | 68 | 0.250 |
Why?
| | Self Report | 2 | 2020 | 695 | 0.250 |
Why?
| | Periodicals as Topic | 2 | 2019 | 181 | 0.240 |
Why?
| | Risk Factors | 9 | 2022 | 8627 | 0.240 |
Why?
| | Clinical Trials as Topic | 3 | 2024 | 935 | 0.230 |
Why?
| | Bayes Theorem | 2 | 2022 | 331 | 0.230 |
Why?
| | Janus Kinase Inhibitors | 1 | 2023 | 10 | 0.230 |
Why?
| | Budesonide, Formoterol Fumarate Drug Combination | 1 | 2023 | 1 | 0.230 |
Why?
| | Histamine Antagonists | 2 | 2023 | 20 | 0.230 |
Why?
| | Infant Food | 2 | 2022 | 63 | 0.230 |
Why?
| | Australia | 3 | 2020 | 207 | 0.220 |
Why?
| | Food, Formulated | 2 | 2020 | 14 | 0.220 |
Why?
| | State Medicine | 1 | 2023 | 18 | 0.220 |
Why?
| | Diagnosis, Differential | 4 | 2021 | 1340 | 0.220 |
Why?
| | Insecta | 2 | 2017 | 65 | 0.210 |
Why?
| | Chicago | 2 | 2022 | 45 | 0.210 |
Why?
| | Immunologic Factors | 2 | 2022 | 220 | 0.210 |
Why?
| | Patient Safety | 2 | 2018 | 278 | 0.210 |
Why?
| | Dermatologic Agents | 1 | 2023 | 57 | 0.210 |
Why?
| | Dilatation | 2 | 2020 | 60 | 0.210 |
Why?
| | Emollients | 1 | 2022 | 11 | 0.210 |
Why?
| | Injections | 2 | 2021 | 159 | 0.200 |
Why?
| | Books | 1 | 2022 | 3 | 0.200 |
Why?
| | Guideline Adherence | 2 | 2019 | 490 | 0.200 |
Why?
| | Immunity | 1 | 2023 | 121 | 0.200 |
Why?
| | Reproducibility of Results | 3 | 2022 | 2763 | 0.200 |
Why?
| | Nasal Polyps | 1 | 2022 | 49 | 0.200 |
Why?
| | Societies, Medical | 3 | 2020 | 663 | 0.200 |
Why?
| | Prognosis | 3 | 2020 | 3334 | 0.200 |
Why?
| | Lactation | 1 | 2023 | 151 | 0.200 |
Why?
| | Follow-Up Studies | 4 | 2022 | 4420 | 0.200 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2022 | 21 | 0.200 |
Why?
| | Parents | 3 | 2023 | 1190 | 0.200 |
Why?
| | Asparaginase | 1 | 2021 | 29 | 0.200 |
Why?
| | Agammaglobulinemia | 1 | 2022 | 30 | 0.200 |
Why?
| | Emergency Service, Hospital | 3 | 2023 | 1812 | 0.190 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 124 | 0.190 |
Why?
| | Patient Education as Topic | 2 | 2020 | 679 | 0.190 |
Why?
| | Algorithms | 3 | 2021 | 1468 | 0.190 |
Why?
| | Symptom Assessment | 2 | 2020 | 119 | 0.190 |
Why?
| | Child Day Care Centers | 1 | 2021 | 33 | 0.190 |
Why?
| | Drug Prescriptions | 1 | 2023 | 239 | 0.190 |
Why?
| | Family | 3 | 2021 | 591 | 0.180 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 122 | 0.180 |
Why?
| | Esophagoscopy | 2 | 2020 | 184 | 0.180 |
Why?
| | Pilot Projects | 2 | 2018 | 1370 | 0.180 |
Why?
| | Breath Tests | 2 | 2018 | 82 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2023 | 1214 | 0.180 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 117 | 0.180 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2020 | 29 | 0.180 |
Why?
| | Sinusitis | 1 | 2022 | 175 | 0.180 |
Why?
| | Probability | 2 | 2022 | 291 | 0.180 |
Why?
| | Educational Personnel | 1 | 2020 | 13 | 0.180 |
Why?
| | Hoarding | 1 | 2020 | 2 | 0.180 |
Why?
| | Terbutaline | 1 | 2020 | 8 | 0.180 |
Why?
| | Military Medicine | 1 | 2022 | 93 | 0.180 |
Why?
| | North America | 1 | 2021 | 257 | 0.170 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 28 | 0.170 |
Why?
| | Antibody Specificity | 2 | 2017 | 176 | 0.170 |
Why?
| | beta-Lactams | 1 | 2020 | 27 | 0.170 |
Why?
| | Mass Media | 1 | 2020 | 37 | 0.170 |
Why?
| | Plant Bark | 1 | 2019 | 11 | 0.170 |
Why?
| | Precision Medicine | 2 | 2020 | 338 | 0.170 |
Why?
| | Drug Approval | 1 | 2020 | 78 | 0.170 |
Why?
| | Albuterol | 1 | 2020 | 102 | 0.170 |
Why?
| | Access to Information | 1 | 2020 | 47 | 0.170 |
Why?
| | Insurance Claim Review | 1 | 2020 | 67 | 0.170 |
Why?
| | Equipment Failure | 1 | 2020 | 106 | 0.170 |
Why?
| | Europe | 2 | 2018 | 336 | 0.170 |
Why?
| | Syndrome | 2 | 2017 | 334 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2021 | 135 | 0.170 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 225 | 0.170 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6350 | 0.160 |
Why?
| | Network Meta-Analysis | 3 | 2023 | 15 | 0.160 |
Why?
| | Monte Carlo Method | 1 | 2019 | 137 | 0.160 |
Why?
| | Public Facilities | 1 | 2019 | 5 | 0.160 |
Why?
| | Transdermal Patch | 1 | 2019 | 15 | 0.160 |
Why?
| | Pollen | 1 | 2019 | 24 | 0.160 |
Why?
| | False Negative Reactions | 1 | 2019 | 48 | 0.160 |
Why?
| | Infant Behavior | 1 | 2019 | 23 | 0.160 |
Why?
| | Crying | 1 | 2019 | 15 | 0.160 |
Why?
| | False Positive Reactions | 1 | 2019 | 108 | 0.160 |
Why?
| | Benchmarking | 1 | 2020 | 161 | 0.160 |
Why?
| | Equipment Design | 1 | 2020 | 508 | 0.160 |
Why?
| | Income | 2 | 2023 | 167 | 0.160 |
Why?
| | Drugs, Generic | 1 | 2018 | 18 | 0.160 |
Why?
| | Models, Economic | 1 | 2019 | 48 | 0.160 |
Why?
| | Cost Savings | 1 | 2019 | 74 | 0.160 |
Why?
| | Needles | 1 | 2019 | 49 | 0.160 |
Why?
| | Reference Standards | 1 | 2019 | 159 | 0.160 |
Why?
| | Public Health Surveillance | 1 | 2018 | 61 | 0.150 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 501 | 0.150 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 25 | 0.150 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.150 |
Why?
| | Virtual Reality | 1 | 2019 | 38 | 0.150 |
Why?
| | Patient Preference | 1 | 2020 | 167 | 0.150 |
Why?
| | New Zealand | 1 | 2018 | 41 | 0.150 |
Why?
| | Vomiting | 1 | 2019 | 123 | 0.150 |
Why?
| | Biopsy | 3 | 2019 | 1040 | 0.150 |
Why?
| | Exanthema | 1 | 2019 | 74 | 0.150 |
Why?
| | Respiratory Sounds | 1 | 2019 | 111 | 0.150 |
Why?
| | Pruritus | 3 | 2023 | 60 | 0.150 |
Why?
| | Heparin | 1 | 2019 | 222 | 0.150 |
Why?
| | Cough | 1 | 2019 | 107 | 0.150 |
Why?
| | Work Performance | 1 | 2018 | 6 | 0.150 |
Why?
| | Hydrolysis | 1 | 2018 | 175 | 0.150 |
Why?
| | Travel | 1 | 2019 | 121 | 0.150 |
Why?
| | Eating | 2 | 2019 | 345 | 0.150 |
Why?
| | Information Dissemination | 1 | 2020 | 187 | 0.150 |
Why?
| | RNA, Viral | 1 | 2021 | 566 | 0.150 |
Why?
| | Early Medical Intervention | 1 | 2018 | 51 | 0.150 |
Why?
| | Aged | 5 | 2022 | 19094 | 0.150 |
Why?
| | Immune Sera | 1 | 2017 | 79 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2018 | 124 | 0.150 |
Why?
| | Nasal Obstruction | 1 | 2017 | 23 | 0.140 |
Why?
| | Mothers | 1 | 2023 | 651 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 287 | 0.140 |
Why?
| | Uncertainty | 1 | 2017 | 96 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 452 | 0.140 |
Why?
| | Venoms | 1 | 2017 | 30 | 0.140 |
Why?
| | Transgenes | 1 | 2017 | 170 | 0.140 |
Why?
| | Asthma, Exercise-Induced | 1 | 2016 | 7 | 0.140 |
Why?
| | Bronchoconstriction | 1 | 2016 | 26 | 0.140 |
Why?
| | Linear Models | 2 | 2020 | 770 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 524 | 0.140 |
Why?
| | Behavior | 1 | 2017 | 92 | 0.130 |
Why?
| | Fatty Acids | 1 | 2019 | 382 | 0.130 |
Why?
| | Phenotype | 3 | 2020 | 2812 | 0.130 |
Why?
| | Environmental Pollutants | 1 | 2018 | 110 | 0.130 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 718 | 0.130 |
Why?
| | Observer Variation | 1 | 2016 | 295 | 0.130 |
Why?
| | Health Surveys | 2 | 2020 | 443 | 0.130 |
Why?
| | Hospitals, Special | 1 | 2015 | 10 | 0.130 |
Why?
| | Tertiary Healthcare | 1 | 2015 | 29 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2017 | 222 | 0.130 |
Why?
| | Protein-Losing Enteropathies | 1 | 2015 | 11 | 0.120 |
Why?
| | Computer Simulation | 1 | 2019 | 878 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 195 | 0.120 |
Why?
| | Patient Selection | 1 | 2019 | 641 | 0.120 |
Why?
| | Lymphopenia | 1 | 2015 | 50 | 0.120 |
Why?
| | Hospitalization | 2 | 2021 | 1752 | 0.120 |
Why?
| | Michigan | 1 | 2014 | 96 | 0.120 |
Why?
| | Self Efficacy | 1 | 2018 | 355 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2017 | 413 | 0.120 |
Why?
| | Hypertension | 1 | 2022 | 1059 | 0.120 |
Why?
| | Inhalation | 1 | 2014 | 26 | 0.110 |
Why?
| | Population Surveillance | 1 | 2017 | 392 | 0.110 |
Why?
| | Injections, Subcutaneous | 1 | 2014 | 134 | 0.110 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 521 | 0.110 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2013 | 76 | 0.110 |
Why?
| | Skin | 1 | 2018 | 659 | 0.110 |
Why?
| | Perioperative Period | 1 | 2013 | 49 | 0.110 |
Why?
| | Government Regulation | 1 | 2013 | 46 | 0.110 |
Why?
| | Fontan Procedure | 1 | 2015 | 157 | 0.110 |
Why?
| | Medication Adherence | 1 | 2017 | 537 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 1727 | 0.100 |
Why?
| | Prebiotics | 2 | 2023 | 23 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2023 | 642 | 0.100 |
Why?
| | Biomarkers | 2 | 2020 | 3416 | 0.100 |
Why?
| | Disease Progression | 2 | 2020 | 2387 | 0.090 |
Why?
| | Clinical Competence | 1 | 2017 | 896 | 0.090 |
Why?
| | Triticum | 1 | 2010 | 9 | 0.090 |
Why?
| | Pyroglyphidae | 2 | 2022 | 17 | 0.090 |
Why?
| | Residence Characteristics | 1 | 2012 | 275 | 0.090 |
Why?
| | Immunization, Secondary | 1 | 2010 | 82 | 0.090 |
Why?
| | Lung | 2 | 2024 | 3546 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 689 | 0.090 |
Why?
| | Adrenergic Agonists | 1 | 2009 | 4 | 0.090 |
Why?
| | Aviation | 1 | 2009 | 9 | 0.080 |
Why?
| | Food Coloring Agents | 1 | 2009 | 1 | 0.080 |
Why?
| | Histamine H1 Antagonists | 1 | 2009 | 33 | 0.080 |
Why?
| | Hemiptera | 1 | 2009 | 3 | 0.080 |
Why?
| | Comprehension | 1 | 2011 | 155 | 0.080 |
Why?
| | Empathy | 1 | 2011 | 138 | 0.080 |
Why?
| | Physician's Role | 1 | 2011 | 197 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 965 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1846 | 0.080 |
Why?
| | Tablets | 1 | 2009 | 36 | 0.080 |
Why?
| | Cardiac Surgical Procedures | 1 | 2013 | 413 | 0.080 |
Why?
| | Coloring Agents | 1 | 2009 | 72 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 1717 | 0.080 |
Why?
| | Heart Defects, Congenital | 1 | 2015 | 665 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2016 | 944 | 0.080 |
Why?
| | Primary Health Care | 2 | 2021 | 1515 | 0.080 |
Why?
| | Arthropod Venoms | 1 | 2007 | 2 | 0.070 |
Why?
| | Tryptases | 1 | 2007 | 10 | 0.070 |
Why?
| | Occupational Diseases | 1 | 2009 | 128 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.070 |
Why?
| | Vitamin D | 2 | 2022 | 341 | 0.070 |
Why?
| | Data Collection | 1 | 2009 | 622 | 0.070 |
Why?
| | Risk-Taking | 1 | 2009 | 333 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1796 | 0.060 |
Why?
| | Adaptation, Psychological | 2 | 2020 | 547 | 0.060 |
Why?
| | Formoterol Fumarate | 1 | 2023 | 7 | 0.060 |
Why?
| | Ethanolamines | 1 | 2023 | 19 | 0.060 |
Why?
| | Budesonide | 1 | 2023 | 87 | 0.050 |
Why?
| | Beneficence | 1 | 2023 | 18 | 0.050 |
Why?
| | Dermatophagoides pteronyssinus | 1 | 2022 | 3 | 0.050 |
Why?
| | Drug Combinations | 1 | 2023 | 286 | 0.050 |
Why?
| | Sample Size | 1 | 2023 | 114 | 0.050 |
Why?
| | Moscow | 1 | 2022 | 1 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2021 | 801 | 0.050 |
Why?
| | Administration, Intranasal | 1 | 2022 | 75 | 0.050 |
Why?
| | Tacrolimus | 1 | 2023 | 134 | 0.050 |
Why?
| | Ukraine | 1 | 2022 | 9 | 0.050 |
Why?
| | Baths | 1 | 2022 | 17 | 0.050 |
Why?
| | Dietary Fiber | 1 | 2022 | 40 | 0.050 |
Why?
| | Geography | 1 | 2022 | 180 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 249 | 0.050 |
Why?
| | Child, Hospitalized | 1 | 2022 | 38 | 0.050 |
Why?
| | Forecasting | 1 | 2023 | 331 | 0.050 |
Why?
| | History, 20th Century | 1 | 2022 | 265 | 0.050 |
Why?
| | Russia | 1 | 2020 | 9 | 0.050 |
Why?
| | Patient Care Management | 1 | 2021 | 53 | 0.050 |
Why?
| | Milk, Human | 1 | 2022 | 128 | 0.040 |
Why?
| | London | 1 | 2020 | 43 | 0.040 |
Why?
| | Professionalism | 1 | 2020 | 14 | 0.040 |
Why?
| | Guilt | 1 | 2020 | 11 | 0.040 |
Why?
| | Patient Care Planning | 1 | 2021 | 139 | 0.040 |
Why?
| | Grief | 1 | 2020 | 35 | 0.040 |
Why?
| | Health Care Rationing | 1 | 2020 | 45 | 0.040 |
Why?
| | Aspirin | 1 | 2022 | 324 | 0.040 |
Why?
| | Risk Management | 1 | 2021 | 89 | 0.040 |
Why?
| | Expert Testimony | 1 | 2020 | 36 | 0.040 |
Why?
| | Publication Bias | 1 | 2020 | 36 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 1843 | 0.040 |
Why?
| | Biological Variation, Individual | 1 | 2019 | 2 | 0.040 |
Why?
| | No-Observed-Adverse-Effect Level | 1 | 2019 | 5 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 647 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 84 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 167 | 0.040 |
Why?
| | Placebo Effect | 1 | 2019 | 51 | 0.040 |
Why?
| | Spirituality | 1 | 2020 | 69 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 184 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 182 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 114 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 385 | 0.040 |
Why?
| | Hematologic Tests | 1 | 2018 | 22 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 296 | 0.040 |
Why?
| | Mindfulness | 1 | 2020 | 97 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2019 | 309 | 0.040 |
Why?
| | Th1-Th2 Balance | 1 | 2018 | 9 | 0.040 |
Why?
| | Poverty | 1 | 2021 | 442 | 0.040 |
Why?
| | Hygiene | 1 | 2018 | 27 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 580 | 0.040 |
Why?
| | Endoscopy, Digestive System | 1 | 2019 | 110 | 0.040 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.040 |
Why?
| | Social Behavior | 1 | 2020 | 268 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1122 | 0.040 |
Why?
| | Dietetics | 1 | 2017 | 22 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2019 | 539 | 0.040 |
Why?
| | Societies, Scientific | 1 | 2017 | 47 | 0.040 |
Why?
| | Research | 1 | 2020 | 394 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 37 | 0.030 |
Why?
| | Protective Factors | 1 | 2017 | 87 | 0.030 |
Why?
| | Bias | 1 | 2017 | 180 | 0.030 |
Why?
| | Child Abuse | 1 | 2021 | 450 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 184 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2020 | 479 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 769 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2019 | 446 | 0.030 |
Why?
| | Perception | 1 | 2018 | 311 | 0.030 |
Why?
| | Immunoglobulin Isotypes | 1 | 2015 | 32 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2017 | 311 | 0.030 |
Why?
| | Eye Diseases | 1 | 2016 | 76 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2015 | 257 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 954 | 0.030 |
Why?
| | Respiratory Tract Diseases | 1 | 2016 | 139 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1270 | 0.030 |
Why?
| | Suicide | 1 | 2020 | 502 | 0.030 |
Why?
| | Emotions | 1 | 2018 | 472 | 0.030 |
Why?
| | Anesthesia, General | 1 | 2013 | 45 | 0.030 |
Why?
| | Anesthetics | 1 | 2013 | 54 | 0.030 |
Why?
| | Quality Improvement | 1 | 2020 | 951 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2018 | 723 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2020 | 755 | 0.020 |
Why?
| | Depression | 1 | 2020 | 1133 | 0.020 |
Why?
| | Substance-Related Disorders | 1 | 2020 | 947 | 0.020 |
Why?
| | Anesthesia | 1 | 2013 | 117 | 0.020 |
Why?
| | Diarrhea | 1 | 2012 | 173 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2012 | 135 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2099 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 936 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3542 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3005 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4522 | 0.020 |
Why?
|
|
Greenhawt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|